The NIH delayed a clinical trial for DIPG. That's diffuse intrinsic pontine glioma. A brain tumor that kills children. Survival rate sits around zero percent. Treatment options match that number.
Federal research funding got cut. The trial got pushed back. Kids with DIPG don't have time to wait because the median survival is nine months. But at least someone's portfolio is perfectly hedged against a 25-basis-point rate cut.
This is what matters. Not earnings. Not guidance. Not whether some f*cking semiconductor company beat estimates by two cents. A promising treatment sits on a shelf because the money dried up. Children lose months they needed. Retail traders lose their minds over a Tesla delivery miss.
The same people who'll buy $40,000 worth of zero-day options on a Wednesday because some guy on Twitter said NVDA looks bullish can't be bothered to understand what happens when research funding disappears. They'll read this headline. Scroll past it. Check if their meme stock is up pre-market. Maybe tweet about how the market's rigged.
DIPG has no cure. Radiation buys a few months. Chemotherapy does almost nothing. Clinical trials represent the only shot. Except when those trials don't happen because the funding falls through. Then kids just die on schedule while grown adults argue about whether JPow blinked twice during his last press conference.
The trial was promising. The word "promising" in pediatric brain cancer research means something. It means someone thought they had a angle worth testing. It means families had hope. Past tense. Because the money moved somewhere else or just vanished into the void where government budgets go to die.
You can chart this. Plot childhood cancer survival rates against S&P returns. Guess which line retail gives a sh*t about.
Photo by National Cancer Institute on Unsplash
Leave a Comment